

Market Scope[®]

2022 Glaucoma Device Market Report

Global Analysis for 2021 to 2027

\$789M

2022 MARKET
FORECAST

300

COMPREHENSIVE
PAGES

24

COMPETITOR
PROFILES

8

GEOGRAPHIC AND
ECONOMIC BREAKOUTS

What's New

AUTHOR
William Freeman

PUBLISHED
August 2022

The new “2022 Glaucoma Surgical Device Market Report” redefines glaucoma surgical products by aqueous drainage location and in accordance with the way surgeons refer to products. It also provides an analysis of the COVID-19 pandemic’s impact on glaucoma surgery and the market’s rebound by year from 2020 to 2027.

The report focuses on novel microstents in various stages of development and commercialization that are expected to be used in more advanced stages of glaucoma, as well as standalone glaucoma surgery, rather than only in combined cataract/glaucoma procedures.


Market Scope

2022 Glaucoma Surgical Device Market Report


The “2022 Glaucoma Surgical Device Market Report” offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends and key factors shaping future success. The report covers prevalence for glaucoma worldwide and discusses the ophthalmologists who treat glaucoma. It also examines the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Coverage includes:

- Background information about glaucoma, glaucoma populations, and glaucoma diagnosis.
- Estimates of current sales and sales forecasts for glaucoma devices, including average prices and total revenue.
- Profiles of prospective device buyers, including ophthalmologists, ophthalmic specialists, optometrists, and general medical doctors.
- Information about manufacturers.
- Current reimbursement rates.
- Analysis on the percentage of the different types of glaucoma surgeries being performed by US cataract surgeons, glaucoma specialists, and general ophthalmologists.
- Tracking of the progress being made in sustained drug delivery devices in a separate section of the report.

Global Glaucoma Surgery Treatment Mix— Historical and Projected



Competitors in the Market by Revenue Share



In addition, the report analyzes a handful of novel glaucoma surgery devices that have the potential to dramatically expand glaucoma surgery, including the Alievio adjustable shunt, Avisi Technologies microshunt, CorNeat Vision eShunt, Glaukos iStent Infinite, MicroOptx Beacon shunt, Rheon Medical eyeWatch adjustable shunt, and Sanoculis Minimally Invasive Microsclerostomy (MIMS) device. Further, the report looks at new laser technologies that have the potential to dramatically expand the use of lasers in glaucoma, including the Belkin laser, ViaLase femtosecond laser, Elios ELT Laser, and IOptimate CO2 laser.

How to Order

Order your “2022 Glaucoma Surgical Device Market Report” now at www.market-scope.com or contact us directly via email or phone.



ENTERPRISE LICENSE

2022 Glaucoma Surgical
Device Market Report

\$11,200

(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)



SINGLE-USER LICENSE

2022 Glaucoma Surgical
Device Market Report

\$7,500



Printed Copy

\$250



ONE-YEAR SUBSCRIPTION

Ophthalmic Market
Perspectives Newsletter

\$1,500



Monthly Paper Copies

\$100

314.835.0600 | info@market-scope.com

Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

